Elena Robinson

Elena Robinson

Auto-generated profile, based on publicly available information

Elena Robinson

Division of Infectious Diseases and Hospital Epidemiology, Children’s Research Center, University Children’s Hospital Zurich, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
ERElena Robinson
Elena Robinson
MZMichael Zellner
Michael Zellner
EOEster Osuna
Ester Osuna
MSMichelle Seiler
Michelle Seiler
MTMartin Theiler
Martin Theiler
PSPatrick M. Meyer Sauteur
Patrick M. Meyer Sauteur
Since its delayed re-emergence after non-pharmaceutical interventions (NPIs) against the COVID-19 pandemic, Mycoplasma pneumoniae has caused community-acquired pneumonia outbreaks worldwide. In this study, we aimed to investigate how the clinical characteristics and severity of M. pneumoniae infections have changed after COVID-19 pandemic restriction, in order to enable adequate interpretation of clinical features and response to future M. pneumoniae epidemics. This retrospective, comparative cohort study compared clinical features and severity of children with M. pneumoniae detection by PCR during the periods April 1, 2015, to March 31, 2020 (pre-NPI); April 1, 2020, to March 31, 2022 (NPI); and April 1, 2022, to March 31, 2025 (post-NPI). Clinical features were compared between periods by Kruskal–Wallis rank sum test or Fisher’s exact test, as appropriate. Moreover, we compared hospitalization and intensive care unit (ICU) admission using generalized linear models. In total, 321 patients were included in the study. Since the first detection of M. pneumoniae after the COVID-19 pandemic in summer 2023, the re-emergence has shown a bimodal curve with two distinct peaks (post-NPI first-year and second-year). The median age of patients was higher in the post-NPI than the pre-NPI period (9.05 vs 8.20 years), particularly during the first-year peak (11.00 years). Obstructive diseases were observed more frequently post-NPI compared to pre-NPI (18.6% vs 9.6%). Moreover, more patients presented with chest pain (8.9% vs 2.4%) and pleural effusions (45.7% vs 28.9%) post-NPI than pre-NPI. Conversely, extrapulmonary manifestations were less frequent post-NPI (18.6% vs 30.1%), particularly dermatological (15.7% vs 25.3%) and neurological (1.3% vs 4.8%) manifestations. Hospitalization rate (38.6% post-NPI vs 43.9% pre-NPI) and length of stay (median, 4 [IQR, 2–5] vs 4 [IQR, 3–6] days) were similar, while generalized linear models showed a trend toward fewer hospitalizations post-NPI (odds ratio [OR], 0.72 [95% CI, 0.42–1.23]; P = 0.22). The same applied to ICU admission rate (5.1% post-NPI vs 4.9% pre-NPI), with a trend toward fewer ICU admissions post-NPI (OR, 0.90 [95% CI, 0.29–3.34]; P = 0.86). Conclusion : We observed notable changes in the clinical presentation of re-emerging M. pneumoniae infections compared to the pre-COVID-19 pandemic period, particularly an increase in obstructive phenotypes and pleural effusions. However, overall disease severity appeared to remain largely unchanged. What is Known: • The delayed re-emergence of M. pneumoniae in late 2023 was substantial in terms of case numbers across many geographical locations. • No statistically increased proportion of severe or worse outcomes of re-emerging M. pneumoniae infections could be observed globally compared with pre-COVID-19 pandemic epidemics. What is New: • Clinical features of M. pneumoniae infections in children partly changed following COVID-19 pandemic restrictions, with new signs like obstructive phenotypes and pleural effusions. • The findings suggest that there has been no overall increase in disease severity; in fact, extrapulmonary manifestations were fewer, with trends toward reduced hospitalizations and ICU admissions.

6 February 2026 in Journal of Medical Microbiology
Verified
Journal Article
Open access
BGBeat M. Greiter
Beat M. Greiter
SSSemjon Sidorov
Semjon Sidorov
EOEster Osuna
Ester Osuna
ASAnnina Schalch
Annina Schalch
LGLisa M. Greiter
Lisa M. Greiter
PSPatrick M. Meyer Sauteur
Patrick M. Meyer Sauteur
Introduction. Direct detection of Borrelia burgdorferi by culture is considered the gold standard for confirming Lyme disease (LD). However, B. burgdorferi culture is not routinely used in clinical practice or research due to its lengthy protocol and low success rate. This study aimed to streamline the process by integrating a specific quantitative PCR (qPCR) screening early into the B. burgdorferi culture workflow for identification of cultures that are likely to yield viable spirochetes. Methods. Thirty-two blood plasma and 11 cerebrospinal fluid (CSF) samples were collected from 32 children with serologically confirmed LD and incubated in modified Kelly-Pettenkofer medium for up to 9 weeks, with weekly assessments for viable spirochetes using microscopy. After 3 weeks, the presence of B. burgdorferi DNA in culture was assessed by qPCR targeting the B. burgdorferi flagellin B gene. The estimated copy number of the target template was compared to the assay’s 95% limit of detection (LOD). Results. After 9 weeks of incubation, viable spirochetes were observed in 2 ( n =2/32, 6.3%) plasma cultures and 3 ( n =3/11, 27.3%) CSF cultures. These were only observed in cultures showing copy numbers above 95% LOD in qPCR testing at week 3 ( n =2/3 plasma cultures, 66.7%; n =3/3 CSF cultures, 100.0%). Conclusion. Culturing B. burgdorferi is challenging and, despite a high workload, often not successful. qPCR may serve as an effective screening tool for B. burgdorferi cultures, enabling the culturing process to be streamlined by prioritizing cultures with target copy numbers exceeding the 95% LOD of the qPCR assay.

26 May 2026 in The Lancet Microbe
Verified
Journal Article
Open access
XZXu-Sheng Zhang
Xu-Sheng Zhang
SSSemjon Sidorov
Semjon Sidorov
UDUrsula Dalrymple
Ursula Dalrymple
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
SUSøren Anker Uldum
Søren Anker Uldum
MBMichael Leslie Beeton
Michael Leslie Beeton

28 November 2025 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
ERElena Robinson
Elena Robinson
SFStefanie von Felten
Stefanie von Felten
PSPatrick M. Meyer Sauteur
Patrick M. Meyer Sauteur

14 October 2026 in Infection
Verified
Journal Article
Open access
PDF file
ERElena Robinson
Elena Robinson
SFStefanie von Felten
Stefanie von Felten
PSPatrick M. Meyer Sauteur
Patrick M. Meyer Sauteur
Purpose: To determine whether upper respiratory tract co-detection of human rhino-/enterovirus is associated with a distinct clinical phenotype in children with Mycoplasma pneumoniae infection. Methods: We analyzed 236 children with M. pneumoniae infection detected by multiplex polymerase chain reaction (PCR) from 2022 to 2025 at the University Children’s Hospital Zurich, comparing those without and with human rhino-/enterovirus co-detection, and performing a secondary analysis after excluding other co-detections. Results: No statistically significant differences were observed in demographic characteristics, clinical presentation, or inflammatory markers between groups. Conclusion: Human rhino-/enterovirus co-detection may represent incidental viral detection rather than clinically relevant co-infection in children with M. pneumoniae infection, supporting cautious interpretation of multiplex PCR results.